President Donald Trump announced that the TrumpRx online drug-coupon platform is adding more than 600 [1] generic medications to its service.
This expansion aims to lower costs for Medicare and Medicaid beneficiaries by increasing access to affordable prescriptions and promoting price transparency. The move reflects an effort to reduce the financial burden of healthcare on vulnerable populations through direct price intervention.
Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, said the rollout during an appearance on the Morning Joe program. The discussion focused on how the addition of these generic options will integrate with existing government health programs to provide immediate relief to patients.
The announcement was first reported on April 27, 2026 [2], following a Monday rollout. According to reports, the administration has signed deals with nearly every major drugmaker to facilitate the platform's growth. The initiative seeks to create a more competitive environment for prescription pricing by leveraging a centralized coupon system.
Dr. Oz said the rollout is designed to improve the efficiency of drug delivery and cost management. The integration of more than 600 [1] generic drugs is intended to provide alternatives to expensive brand-name medications, which often drive up the cost of public health spending.
The administration is positioning TrumpRx as a primary tool for transparency, allowing users to compare prices, and access discounts more easily. By expanding the catalog of available generics, the government intends to put downward pressure on pharmaceutical pricing across the U.S. healthcare market.
“TrumpRx is adding over 600 generic medications to its service.”
The expansion of TrumpRx represents a shift toward a coupon-based model for reducing pharmaceutical costs, bypassing traditional pharmacy benefit manager negotiations. By adding a significant volume of generics, the administration is attempting to lower the out-of-pocket costs for Medicare and Medicaid recipients while using a public platform to signal price expectations to the broader drug market.
